-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $27

Benzinga·08/07/2026 18:20:55
Listen to the news
JP Morgan analyst Brian Cheng maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and lowers the price target from $31 to $27.